Humacyte Inc (HUMA)
5.95
-0.47
(-7.32%)
USD |
NASDAQ |
May 17, 11:44
Humacyte Cash from Financing (TTM): 67.71M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 67.71M |
December 31, 2023 | 4.507M |
September 30, 2023 | 4.63M |
June 30, 2023 | 5.105M |
March 31, 2023 | -1.394M |
Date | Value |
---|---|
December 31, 2022 | -1.446M |
September 30, 2022 | 5.312M |
June 30, 2022 | 247.68M |
March 31, 2022 | 247.25M |
December 31, 2021 | 266.98M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-1.446M
Minimum
Dec 2022
266.98M
Maximum
Dec 2021
84.63M
Average
5.208M
Median
Cash from Financing (TTM) Benchmarks
Adial Pharmaceuticals Inc | 4.132M |
Gritstone Bio Inc | 16.09M |
Precision BioSciences Inc | 44.74M |
Puma Biotechnology Inc | 0.00 |
Revance Therapeutics Inc | 226.13M |